Novo Nordisk Faces Boardroom Turmoil as It Aims for U.S. Weight-Loss Market Revival

Novo Nordisk faces boardroom turmoil as it strives to reclaim its position in the U.S. weight-loss market, currently overshadowed by rivals and external pressures.

• Novo Nordisk has experienced a decline in market leadership for its obesity drug, Semaglutide, due to rising competition from Eli Lilly and cheaper alternatives.
• The companys top shareholder, the Novo Nordisk Foundation, has expressed concerns about the managements strategy to regain market share in the U.S. weight-loss drug sector.
• Pressure from U.S. President Donald Trumps administration regarding drug pricing and an increase in direct-to-consumer sales have intensified challenges for Novo Nordisk in the American market.